3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Multiple Myeloma
10
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm Metastasis
4
Lymphoma
4
Leukemia
4
Hodgkin Disease
4
Burkitt Lymphoma
4
Breast Neoplasms
4
Vomiting
3
Prostatic Neoplasms
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Leukemia, Hairy Cell
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Stomatitis
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Nausea
2
Myelodysplastic Syndromes
2
Mucositis
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Interventions
Cisplatin
274
pembrolizumab
229
Radiotherapy
166
Cetuximab
163
Carboplatin
122
Docetaxel
109
Paclitaxel
94
Fluorouracil
94
Nivolumab
84
Radiotherapy, Intensity-Modulated
78
Magnetic Resonance Spectroscopy
39
durvalumab
35
Radiation
32
Surgical Procedures, Operative
31
Drug Therapy
30
Radiosurgery
25
Erlotinib Hydrochloride
25
Biopsy
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Platinum
22
Specimen Handling
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Capecitabine
19
tremelimumab
18
Ipilimumab
18
Gemcitabine
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Cell Carcinoma of Head and Neck
×
Diphenhydramine
×
Clear all
NCT03107182
2025-05-06
OPTIMA-II
University of Chicago
Phase 2
Completed
72 enrolled
14 charts